| Antiphospholipid
Syndrome
New York University Medical Center
Are new therapies being developed to treat APS?
Pharmaceutical companies are exploring alternative treatment options
for individuals with the antiphospholipid syndrome. One such
company is LaJolla Pharmaceutical Company (LJP). A clinical
trial has recently been initiated by the company to study the safety
of an investigational drug (LJP 1082) for the antiphospholipid syndrome.
What makes this therapy different?
This medication has been developed to treat what is thought to be
an underlying cause of the disease, over-production of immune cells
(B cells) that produce antibodies to the protein B2 GP1. This
therapy is not designed to be a blood thinner, but instead targets
antibodies that bind to a specific region on B2 GP1, and may be
associated with the blood clotting (based on research published
in the National Academy of Science in 1998.)
What Can I do to Help?
Physicians at the Hospital for Joint Diseases at New York University
Medical Center are screening individuals with antiphospholipid antibodies
to see if they might qualify to take part in this clinical trial.
If you have antiphospholipid antibodies and would like
to find out more about this clinical trial, please call 866-757-2757. |